Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Zhen on Advancements in Gastroenteropancreatic Neuroendocrine Tumors

September 7th 2021

David Zhen, MD, discusses advancements in the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

ADP-A2AFP SPEAR T Cells Demonstrate Efficacy, Tolerability in Advanced HCC

September 7th 2021

ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.

Management of Toxicities Is Crucial to Immunotherapy Combination Use in HCC

September 7th 2021

David J. Pinato, MD, discusses combination strategies in HCC, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.

Cancer-Specific Mortality Shows Variable Risk Throughout Neuroendocrine Tumors

September 7th 2021

The risk of cancer-specific death was significantly higher than the risk of noncancer death in patients with neuroendocrine tumors, despite the reported heterogeneity by primary tumor site.

Nivolumab Continues to Elicit Durable Responses in Advanced Hepatocellular Carcinoma

September 7th 2021

Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.

Ongoing Research Pushes Precision Oncology Mindset in Gastrointestinal Cancers

September 6th 2021

E. Gabriela Chiorean, MD, discusses some of the recent developments in pancreatic cancer, HCC, and NETs, as well as multidisciplinary approaches for treating these patients.

Investigators Look to Overcome Resistance in Advanced HCC With Triplet Combinations

September 5th 2021

Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.

Dr. Pinato on Guidelines for Toxicity Management in HCC

September 5th 2021

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).

Atezolizumab/Bevacizumab Improves OS in Albumin-Bilirubin Grade 1 HCC

September 5th 2021

The combination of atezolizumab and bevacizumab elicited an improved overall survival benefit compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma, according to findings from an exploratory subgroup analysis of the phase 3 IMbrave150 trial.

High Interferon Signaling and Antigen Presentation Predicts for Response Only in Frontline Advanced HCC

September 5th 2021

Biomarkers of response to immunotherapy, characterized by high interferon signaling and expression of MHC-II related genes, predicted for improved survival in patients with advanced hepatocellular carcinoma following immediate treatment with a PD-1 inhibitor but not in those who had first received treatment with a TKI.

Dr. Vogel on the Utility of Frontline Lenvatinib or Sorafenib in HCC

September 4th 2021

Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.

Dr. Singal on the Results of a Mailed Outreach Strategy for Surveillance Utilization in HCC

September 4th 2021

Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.

Dr. Rich on the Prevalence of Cachexia in HCC

September 4th 2021

Nicole Rich, MD, discusses the prevalence of cachexia in hepatocellular carcinoma.

SIRT With Y90 Plus Chemotherapy Extends Survival for Intrahepatic Cholangiocarcinoma

September 4th 2021

The addition of selective internal radiation therapy with Y90 resin microspheres to gemcitabine/cisplatin resulted in a median overall survival of 21.6 months for patients with inoperable intrahepatic cholangiocarcinoma, according to prospective phase 2 data.

Dual Checkpoint Blockade/Ablation Regimens Show Intriguing Activity in Advanced HCC

September 4th 2021

Combining durvalumab and tremelimumab plus transcatheter arterial chemoembolization or radiofrequency ablation was found to be both efficacious and safe as a treatment for patients with advanced hepatocellular carcinoma, according to results of a pilot study.

Predictive Biomarkers for Checkpoint Inhibition Remain Unmet Need in HCC

September 3rd 2021

Josep M. Llovet, MD, discusses the importance of identifying biomarkers of response to checkpoint inhibitors for patients with hepatocellular carcinoma, as well as future research directions.

Devimistat Plus Gemcitabine/Cisplatin Moves to Phase 2 Setting in Frontline Biliary Tract Cancer

September 3rd 2021

Devimistat in combination with gemcitabine and cisplatin has moved into the phase 2 portion of a phase 1b/2 trial studying the regimen as a first-line treatment for patients with locally advanced unresectable or metastatic biliary tract cancer.

Dr. Harris on IMbrave150 Results With Atezolizumab/Bevacizumab in HCC

September 3rd 2021

William P. Harris, MD, discusses updated data from the phase 3 IMbrave150 study in hepatocellular carcinoma.

Systemic Treatment Advances for Advanced HCC

September 3rd 2021

Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.

Scoring/Classifying Patients With Advanced HCC

September 3rd 2021

Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.